Sheet

PTC/SB/08A (02-03) Approved for use through 04/30/2003, OMB 0851-0031 U.S. Palant and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1925, no persona are required to respond to a collection of information urress it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/634,463 Filing Date August 4, 2003 INFORMATION DISCLOSURE First Named Inventor Robert W. Brueggemeier et al. STATEMENT BY APPLICANT Art Unli (Use 15 many sheets 25 nocessery) Examiner Name Not yet assigned Attorney Docket Number | 22727/04124

U. S. PATENT DOCUMENTS Name of Patentee or Applicant of Cited Document Cite No. Examiner Document Number Publication Date Pages, Columns, Lines, Where MM-DD-YYYY Relevent Passages or Relevent Figures Appear Number-Kind Code\* (/ house) US- 5,420,307 a 05-30-1995 Hagen et al. US- 5,948,808 09-07-1999 8ale USn 6,150,395 11-21-2000 Firestane et al. US-US-US. US-US U\$ US. Π¢ USus. U\$-US. US-US-US-

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Unes, Where Relevant Passages	П	
		Country Code <sup>3</sup> TAMBER <sup>4</sup> Kind Code <sup>5</sup> (# Ionown)	MM-0D-YYYY		Or Relevant Figures Appear	Τ <sup>đ</sup>	
		·		·			
	<u> </u>		<del></del>		ļ	Ш	
					ļ	Ш	
					<u> </u>		

Exeminer	0 0	 . Dala	
Signature	Cl-X	Considered	4/26/04

\*EXAMINER: Initial if reference considered, whether or not clustion is in consommance with MPEP 609. Draw line through clusten if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patient Documents is <u>www.lepto.gov</u> or MPEP 601.01.3 Enter Office that issued the document, by the work-letter code (MIPO Standard ST.3). Per Lapanese patent documents, the indication of the year of the reign of the Emperor must precede the aretis number of the patient document. Indicated document, and the properties and the properties appropriate appropriat Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to the (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the inclinidated case. Any comments on the amount of time you require to complete bits form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradomark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissionar for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (02-03)

Approved for use through 04/30/2003, OMB 0851-0031 d Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Raduction Act of 1995, no persons are Substitute for form 1449/PTO				re required to respond to a collection of information unless it contains a valid QMB control number.  Complete if Known		
Substituti	9 TU 1911 1913/P1			Application Number	10/634,463	
INFORMATION DISCLOSURE				Filing Date	August 4, 2003	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Robert W. Brueggemeier et al.	
				Art Unit	1632	
(Use as many sheets as necessary)			rcussary)	Examiner Name	Not yet assigued	
Sheet	2	of	2	Attorney Docket Number	22727/04124	

Examiner tnitials*	Cite No.'				
v		KIM, YOUNG-WOO et al., "Synthesis and Estrogen Receptor Binding Affinities of 7-Hydrxy-3-(4-hydroxyphenyl)-4H-1-henzopyran-4-ones Containing a Basic Side Chain," Science Direct, Bioorganic & Medicinal Chemistry Letters 13 (2003) 1475-1478.			
u		KIM, YOUNG-WOO et al., "Novel Z-arythlofsoflavones as potential therapsutic agents for bomorne-dependent breast cancer," Nat'l American Chemical Society Meeting, Aug. 18-22-2002 in Boston, MA.			
n		International Search Report from corresponding apple. no. PCT/US03/24520, June 21, 2004.			
····					

Examiner	00	•	Date	4126/04
Signature	1		Considered	4/26/04

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not is conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicants unique citation designation number (optional). 2 Applicant is to piece a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to fills (and by the USPTO to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for raducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Dapartment of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.